1009 related articles for article (PubMed ID: 27208063)
21. B7-H3 targeted antibody-based immunotherapy of malignant diseases.
Michelakos T; Kontos F; Barakat O; Maggs L; Schwab JH; Ferrone CR; Ferrone S
Expert Opin Biol Ther; 2021 May; 21(5):587-602. PubMed ID: 33301369
[No Abstract] [Full Text] [Related]
22. B7-H3/CD276: An Emerging Cancer Immunotherapy.
Zhou WT; Jin WL
Front Immunol; 2021; 12():701006. PubMed ID: 34349762
[TBL] [Abstract][Full Text] [Related]
23. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.
Du H; Hirabayashi K; Ahn S; Kren NP; Montgomery SA; Wang X; Tiruthani K; Mirlekar B; Michaud D; Greene K; Herrera SG; Xu Y; Sun C; Chen Y; Ma X; Ferrone CR; Pylayeva-Gupta Y; Yeh JJ; Liu R; Savoldo B; Ferrone S; Dotti G
Cancer Cell; 2019 Feb; 35(2):221-237.e8. PubMed ID: 30753824
[TBL] [Abstract][Full Text] [Related]
24. Preparation and application of a novel monoclonal antibody specific for human B7-H3.
Shi J; Zhang DL; Cui ZC; Wang HM
Mol Med Rep; 2016 Jul; 14(1):943-8. PubMed ID: 27222007
[TBL] [Abstract][Full Text] [Related]
25. Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy.
Cai D; Li J; Liu D; Hong S; Qiao Q; Sun Q; Li P; Lyu N; Sun T; Xie S; Guo L; Ni L; Jin L; Dong C
Cell Mol Immunol; 2020 Mar; 17(3):227-236. PubMed ID: 31611650
[TBL] [Abstract][Full Text] [Related]
26. B7-H3-targeted CAR-T cell therapy for solid tumors.
Li G; Wang H; Wu H; Chen J
Int Rev Immunol; 2022; 41(6):625-637. PubMed ID: 35855615
[TBL] [Abstract][Full Text] [Related]
27. Anti-B7-H3 monoclonal antibody ameliorates the damage of acute experimental pancreatitis by attenuating the inflammatory response.
Zhuang X; Shen J; Jia Z; Wu A; Xu T; Shi Y; Xu C
Int Immunopharmacol; 2016 Jun; 35():1-6. PubMed ID: 27003113
[TBL] [Abstract][Full Text] [Related]
28. B7-H3 and its role in bone cancers.
He L; Li Z
Pathol Res Pract; 2019 Jun; 215(6):152420. PubMed ID: 31060912
[TBL] [Abstract][Full Text] [Related]
29. Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities.
Li HY; Chen YL; Deng XN; Li HH; Tan J; Liu GJ; Zheng YJ; Pei M; Peng KT; Yue LL; Chen XJ; Liu Y; Zhao YS; Wang CH
Acta Pharmacol Sin; 2023 Nov; 44(11):2322-2330. PubMed ID: 37328649
[TBL] [Abstract][Full Text] [Related]
30. B7-H3 in Brain Malignancies: Immunology and Immunotherapy.
Guo X; Chang M; Wang Y; Xing B; Ma W
Int J Biol Sci; 2023; 19(12):3762-3780. PubMed ID: 37564196
[TBL] [Abstract][Full Text] [Related]
31. B7-H3 in Cancer - Beyond Immune Regulation.
Flem-Karlsen K; Fodstad Ø; Tan M; Nunes-Xavier CE
Trends Cancer; 2018 Jun; 4(6):401-404. PubMed ID: 29860983
[TBL] [Abstract][Full Text] [Related]
32. T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.
Barach YS; Lee JS; Zang X
Trends Mol Med; 2011 Jan; 17(1):47-55. PubMed ID: 20971039
[TBL] [Abstract][Full Text] [Related]
33. Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo.
Ma J; Shang T; Ma P; Sun X; Zhao J; Sun X; Zhang M
Invest New Drugs; 2019 Oct; 37(5):1036-1043. PubMed ID: 30706335
[TBL] [Abstract][Full Text] [Related]
34. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.
Altan M; Pelekanou V; Schalper KA; Toki M; Gaule P; Syrigos K; Herbst RS; Rimm DL
Clin Cancer Res; 2017 Sep; 23(17):5202-5209. PubMed ID: 28539467
[No Abstract] [Full Text] [Related]
35. B7-H3 in tumors: friend or foe for tumor immunity?
Li G; Quan Y; Che F; Wang L
Cancer Chemother Pharmacol; 2018 Feb; 81(2):245-253. PubMed ID: 29299639
[TBL] [Abstract][Full Text] [Related]
36. An Fc-modified monoclonal antibody as novel treatment option for pancreatic cancer.
Lutz MS; Wang K; Jung G; Salih HR; Hagelstein I
Front Immunol; 2024; 15():1343929. PubMed ID: 38322253
[TBL] [Abstract][Full Text] [Related]
37. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic effects of anti-B7-H3 antibody in an ovalbumin-induced mouse asthma model.
Chen ZR; Zhang GB; Wang YQ; Yan YD; Zhou WF; Zhu C; Chen Y; Wang J; Ji W
Ann Allergy Asthma Immunol; 2013 Oct; 111(4):276-81. PubMed ID: 24054363
[TBL] [Abstract][Full Text] [Related]
39. New B7 Family Checkpoints in Human Cancers.
Ni L; Dong C
Mol Cancer Ther; 2017 Jul; 16(7):1203-1211. PubMed ID: 28679835
[TBL] [Abstract][Full Text] [Related]
40. Fully human anti-B7-H3 recombinant antibodies inhibited tumor growth by increasing T cell infiltration.
Li L; Nian S; Liu Q; Zhang B; Jimu W; Li C; Huang Z; Hu Q; Huang Y; Yuan Q
Int Immunopharmacol; 2024 May; 132():111926. PubMed ID: 38552297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
